For peptide microarray-based epitope mappings, an antigen sequence is translated into overlapping peptides. To save costs, the peptide-peptide overlap is frequently reduced to e.g. 10 or 11 amino acids with 15mer peptides, as provided by most commercial suppliers. The peptide-peptide overlap, however, plays an important role for epitope prediction. A reduced peptide-peptide overlap hampers the exact identification of conserved core motifs, the unambiguous itemization of neighbored epitopes in polyclonal samples, or the discrimination of non-specific binders from real epitopes.
Due to our proprietary laser printer-based on-chip synthesis, PEPperPRINT is able to routinely translate antigens into peptide microarrays with a maximum peptide-peptide overlap, e.g. 14 amino acids with 15mer peptides (equals a shift of 1), to provide the maximum amount of epitope coverage and prediction at reasonable costs.

For further information please read the application note “Comparison of High Resolution PEPperMAP® Epitope Mappings with Low Resolution Epitope Mappings” available on the website http://www.pepperprint.com/science/application-notes/.

PEPperCIP epitope mapping

High resolution linear Epitope Mapping is based on an antigen translated into 15 aa overlapping peptides with maximum peptide-peptide overlap of 14 aa (shift 1). The peptides are directly synthesized on the glass slides. The array is subsequently stained with the target antibody that binds to its specific epitope and a secondary antibody that has a fluorescence label. An image of the array is taken with a microarray scanner. Since PEPperPRINT prints spot duplicates, each signal appears in a double row. After data acquisition, the PepSlide® Analyzer software immediately calculates the common motif in the peptide hits, which is the epitope of the target antibody.
On the left two examples of such an epitope mapping are shown, a monoclonal sample binding to a single epitope and a polyclonal sample binding to multiple epitopes. Each array is surrounded by HA (red) and FLAG (green) control peptides.

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • Transglutaminases in Medicine

      03.08.2017 - 05.08.2017
      Debrecen, Hungary

    • 15th Congress on Amino Acids, Peptides and Proteins

      07.08.2017 - 11.08.2017
      Vienna, Austria

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland